NVCT Stock Price, Nuvectis Pharma, Inc. Quote, Chart

Market Summary

USD6.51-0.68

Delayedas of 08 May 2024, 02:55 pm

-9.46%

NVCT Stock Price

View Fullscreen

NVCT RSI Chart

NVCT Valuation

Market Cap

132.0M

Price/Earnings (Trailing)

-5.9

Price/Sales (Trailing)

162.94

Price/Free Cashflow

-8.5

NVCT Price/Sales (Trailing)

NVCT Profitability

Return on Equity

-159.62%

Return on Assets

-113.53%

Free Cashflow Yield

-11.77%

NVCT Fundamentals

NVCT Revenue

Revenue (TTM)

810.0K

Rev. Growth (Yr)

332.69%

Rev. Growth (Qtr)

-7.79%

NVCT Earnings

Earnings (TTM)

-22.4M

Earnings Growth (Yr)

-3.01%

Earnings Growth (Qtr)

37.01%

Breaking Down NVCT Revenue

52 Week Range

6.4518.65

(Low)(High)

Last 7 days

18.1%

Last 30 days

-7.7%

Last 90 days

3.2%

Trailing 12 Months

-52.4%

How does NVCT drawdown profile look like?

NVCT Financial Health

Current Ratio

3.46

NVCT Investor Care

Shares Dilution (1Y)

14.67%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	810.0K	0	0	0
2023	199.0K	259.0K	475.0K	637.0K
2022	40.3K	76.5K	112.8K	149.0K
2021	0	0	0	4.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nuvectis Pharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	bentsur ron	bought	51,450	10.29	5,000	chairman & ceo
Jan 03, 2024	poradosu enrique	acquired	-	-	130,000	chief science & business off
Jan 03, 2024	shemesh shay	acquired	-	-	130,000	chief dev. & ops. officer
Oct 10, 2023	bentsur ron	bought	7,091	11.08	640	chairman & ceo
Oct 09, 2023	bentsur ron	bought	9,287	11.19	830	chairman & ceo
Oct 06, 2023	bentsur ron	bought	2,817	11.27	250	chairman & ceo
Oct 05, 2023	bentsur ron	bought	15,526	11.09	1,400	chairman & ceo
Oct 04, 2023	bentsur ron	bought	19,929	10.95	1,820	chairman & ceo
Aug 16, 2023	bentsur ron	bought	1,742	15.15	115	chairman & ceo
Aug 15, 2023	bentsur ron	bought	3,369	14.34	235	chairman & ceo

Which funds bought or sold NVCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 03, 2024	GSA CAPITAL PARTNERS LLP	added	43.82	94,000	322,000	0.03%
May 03, 2024	TRUST CO OF VERMONT	new	-	4,100	4,100	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	HOLLENCREST CAPITAL MANAGEMENT	unchanged	-	-39.00	2,296	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	8.00	8.00	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-7.28	-14,121	145,591	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.19	-6,000	2,000	-%
Apr 18, 2024	Blue Zone Wealth Advisors, LLC	new	-	117,670	117,670	0.04%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	added	8.51	79,252	1,263,870	0.10%
Apr 11, 2024	FORBES J M & CO LLP	unchanged	-	-4,760	278,800	0.03%

Are Funds Buying or Selling NVCT?

Are funds buying NVCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVCT

No. of Funds

Unveiling Nuvectis Pharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 28, 2024	mosseri marlio charles	15%	2,595,000	SC 13G/A
Feb 06, 2024	pontifax management 4 g.p. (2015) ltd.	5.3%	917,400	SC 13G
Feb 01, 2024	shemesh shay	8.6%	1,491,955	SC 13G/A
Feb 01, 2024	poradosu enrique	8.7%	1,503,819	SC 13G/A
Jan 31, 2024	peters thomas phineas	5.2%	908,475	SC 13G/A
Apr 03, 2023	peters thomas phineas	6.4%	947,658	SC 13G
Feb 13, 2023	poradosu enrique	8.3%	1,218,319	SC 13G
Feb 13, 2023	shemesh shay	8.2%	1,205,865	SC 13G
Jan 09, 2023	mosseri marlio charles	16.3%	2,380,176	SC 13G/A

Recent SEC filings of Nuvectis Pharma, Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Mar 19, 2024	4	Insider Trading
Mar 05, 2024	8-K	Current Report
Mar 05, 2024	10-K	Annual Report
Feb 28, 2024	SC 13G/A	Major Ownership Report
Feb 06, 2024	SC 13G	Major Ownership Report
Feb 01, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Nuvectis Pharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Nuvectis Pharma, Inc. News

Latest updates

Nuvectis Pharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-7.8%	225,000	244,000	277,000	64,000	52,000	82,000	61,000	4,000	2,000	-
S&GA Expenses	-100.0%	-	2,601,000	1,672,000	1,510,000	1,734,000	2,381,000	1,418,000	1,068,000	1,140,000	1,121,000
R&D Expenses	-37.6%	2,660,000	4,265,000	4,486,000	4,262,000	2,367,000	4,397,000	4,520,000	2,505,000	1,805,000	-
Net Income	37.0%	-4,171,000	-6,622,000	-5,881,000	-5,708,000	-4,049,000	-6,696,000	-5,877,000	-3,569,000	-2,943,000	-2,261,000
Net Income Margin	20.9%	-27.63	-34.95	-47.02	-86.22	-101	-128	-129	-175	-392	-3,222
Free Cashflow	-13.2%	-4,358,000	-3,850,000	-3,244,000	-4,083,000	-4,777,000	-3,516,000	-4,424,000	-2,543,000	-3,076,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	2.8%	20.00	19.00	22.00	25.00	16.00	20.00	25.00	14.00	18.00	7.00
Current Assets	2.8%	20.00	19.00	22.00	25.00	16.00	20.00	25.00	14.00	18.00	6.00
Cash Equivalents	1.8%	19.00	19.00	22.00	25.00	16.00	20.00	24.00	14.00	17.00	6.00
Liabilities	-18.5%	6.00	7.00	6.00	5.00	4.00	6.00	4.00	3.00	3.00	2.00
Current Liabilities	-18.5%	6.00	7.00	6.00	5.00	4.00	6.00	4.00	3.00	3.00	2.00
Shareholder's Equity	14.9%	14.00	12.00	17.00	20.00	12.00	14.00	20.00	12.00	15.00	-
Retained Earnings	-7.7%	-58.40	-54.20	-47.60	-41.74	-36.03	-31.98	-25.29	-19.40	-15.80	-12.90
Additional Paid-In Capital	9.0%	72.00	66.00	64.00	62.00	48.00	46.00	46.00	31.00	30.00	2.00
Shares Outstanding	5.4%	18.00	17.00	17.00	17.00	15.00	15.00	14.00	13.00	9.00	5.00
Float	-100.0%	-	60.00	-	-	-	64.00	-	-	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Cashflow From Operations	-13.2%	-4,358	-3,850	-3,244	-4,083	-4,777	-3,516	-4,424	-2,543	-3,076	-	-	-
Share Based Compensation	6.2%	1,296	1,220	1,133	950	1,402	482	559	510	156	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	412.1%	4,696	917	703	13,215	252	-131	14,492	-578	14,027	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NVCT Income Statement

2023-12-31

STATEMENT OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
STATEMENT OF OPERATIONS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
OPERATING EXPENSES:
Research and development	$ 15,380	$ 13,227
General and administrative	7,517	6,007
OPERATING LOSS	(22,897)	(19,234)
Finance income	637	149
NET LOSS	(22,260)	(19,085)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (22,260)	$ (19,085)
BASIC NET LOSS PER COMMON SHARES OUTSTANDING, see Note 6	$ (1.43)	$ (1.51)
DILUTED NET LOSS PER COMMON SHARES OUTSTANDING, see Note 6	$ (1.43)	$ (1.51)
Basic weighted average number of common shares outstanding	15,556,655	12,657,651
Diluted weighted average number of common shares outstanding	15,556,655	12,657,651

NVCT Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

CURRENT ASSETS:

Cash and cash equivalents

$ 19,126

$ 19,993

Other current assets

59

412

TOTAL CURRENT ASSETS

19,185

20,405

TOTAL ASSETS

19,185

20,405

CURRENT LIABILITIES

Accounts payables

2,771

2,910

Payable offering costs

450

Accrued liabilities

415

445

Employee compensation and benefits

3,798

2,381

TOTAL CURRENT LIABILITIES

6,984

6,186

TOTAL LIABILITIES

6,984

6,186

COMMITMENTS AND CONTINGENCIES, see Note 3

SHAREHOLDERS' EQUITY: see Note 4

Common Shares, $0.00001 par value - 60,000,000 shares authorized as of December 31, 2023, and December 31, 2022, respectively, 17,418,886, and 15,190,720 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively

^[1]

Additional paid in capital

66,446

46,204

Accumulated deficit

(54,245)

(31,985)

TOTAL SHAREHOLDERS' EQUITY

12,201

14,219

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$ 19,185

$ 20,405

[1]	Represent amount lower than $1,000 USD.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

CEO	Mr. Ron Bentsur M.B.A.
WEBSITE	nuvectis.com
INDUSTRY	Biotechnology
EMPLOYEES	11

Nuvectis Pharma, Inc. Frequently Asked Questions

What is the ticker symbol for Nuvectis Pharma, Inc.? What does NVCT stand for in stocks?

NVCT is the stock ticker symbol of Nuvectis Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuvectis Pharma, Inc. (NVCT)?

As of Tue May 07 2024, market cap of Nuvectis Pharma, Inc. is 131.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVCT stock?

You can check NVCT's fair value in chart for subscribers.

What is the fair value of NVCT stock?

You can check NVCT's fair value in chart for subscribers. The fair value of Nuvectis Pharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nuvectis Pharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nuvectis Pharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether NVCT is over valued or under valued. Whether Nuvectis Pharma, Inc. is cheap or expensive depends on the assumptions which impact Nuvectis Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVCT.

What is Nuvectis Pharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, NVCT's PE ratio (Price to Earnings) is -5.9 and Price to Sales (PS) ratio is 162.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCT PE ratio will change depending on the future growth rate expectations of investors.